The EPS beat and post-period financing reduce near-term dilution risk and support continued development of NurOwn. Traders should monitor enrollment progress in the Phase 3b trial and any FDA feedback as key catalysts. The stock may re-rate further if clinical milestones are met.
Price Chart
Executive Summary
BrainStorm Cell Therapeutics reported a narrower-than-expected net loss for full-year 2025, with EPS of -$0.20 versus consensus of -$0.36, driven by reduced R&D and G&A spending. The company also announced a $2.0 million post-year-end financing, which bolsters cash runway for its Phase 3b ENDURANCE trial of NurOwn for ALS. Despite minimal revenue, the EPS beat and strategic funding support a bullish sentiment.
Key Financial Metrics
Key Facts
- Net loss per share for 2025 was $1.11, a significant improvement from $2.31 in 2024
- EPS of -$0.20 beat consensus estimate of -$0.36 by 44.4%
- R&D expenses decreased to $4.2M from $4.7M in 2024; G&A dropped to $5.8M from $7.0M
- Cash, cash equivalents, and restricted cash totaled $0.3M as of December 31, 2025, with $2.0M in additional funding secured in February 2026
- Company is advancing Phase 3b ENDURANCE trial for NurOwn in ALS, with patient enrollment expected soon
Financial Impact
Net loss reduced by $1.3M YoY with cost discipline; $2.0M strategic financing post-year-end improves liquidity
Risk Factors
- Minimal revenue generation and ongoing losses raise going concern questions
- Heavy reliance on future financing or partnerships to fund late-stage trials
- Clinical trial failure risk for NurOwn in ALS, given prior mixed results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-037760 |
| Document: tm2610751d1_8k.htm | 0001104659-26-037760 |
| Document: 0001104659-26-037760-index-headers.html | 0001104659-26-037760 |
| Document: 0001104659-26-037760-index.html | 0001104659-26-037760 |
| Document: 0001104659-26-037760.txt | 0001104659-26-037760 |
| 8-K Data (Synthetic) | 0001104659-26-037760 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | EFFECT | $0.7700 $0.8300 | ▼ −7.79% | ▼ −11.61% | $0.7700 (+0.00%) |
May 28, 2026 21w ago | 8-K | $0.7500 $0.7500 | · 0.00% | ▲ +2.52% | $0.7700 (+2.67%) |
May 15, 2026 23w ago | 8-K | $0.6900 $0.6300 | ▲ +8.70% | ▲ +10.31% | $0.7700 (−11.59%) |
Mar 31, 2026 29w ago | 8-K | $0.9500 $0.9100 | ▼ −4.21% | ▼ −7.98% | $0.7700 (−18.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers